| dc.contributor.author |
Poulas, K |
en |
| dc.contributor.author |
Eliopoulos, E |
en |
| dc.contributor.author |
Vatzaki, E |
en |
| dc.contributor.author |
Navaza, J |
en |
| dc.contributor.author |
Kontou, M |
en |
| dc.contributor.author |
Oikonomakos, N |
en |
| dc.contributor.author |
Ravi Acharya, K |
en |
| dc.contributor.author |
Tzartos, SJ |
en |
| dc.date.accessioned |
2014-06-06T06:44:35Z |
|
| dc.date.available |
2014-06-06T06:44:35Z |
|
| dc.date.issued |
2001 |
en |
| dc.identifier.issn |
00142956 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1046/j.1432-1327.2001.02274.x |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/1970 |
|
| dc.subject |
Acetylcholine receptor |
en |
| dc.subject |
Antibody structure |
en |
| dc.subject |
Myasthenia gravis |
en |
| dc.subject |
X-ray crystallography |
en |
| dc.subject.other |
cholinergic receptor |
en |
| dc.subject.other |
cholinergic receptor antibody |
en |
| dc.subject.other |
immunoglobulin f(ab) fragment 198 |
en |
| dc.subject.other |
immunoglobulin f(ab) fragment d1 3 |
en |
| dc.subject.other |
monoclonal antibody |
en |
| dc.subject.other |
unclassified drug |
en |
| dc.subject.other |
alpha chain |
en |
| dc.subject.other |
analytic method |
en |
| dc.subject.other |
animal cell |
en |
| dc.subject.other |
antibody structure |
en |
| dc.subject.other |
antigen binding |
en |
| dc.subject.other |
article |
en |
| dc.subject.other |
autoimmune disease |
en |
| dc.subject.other |
binding site |
en |
| dc.subject.other |
complementarity determining region |
en |
| dc.subject.other |
computer program |
en |
| dc.subject.other |
controlled study |
en |
| dc.subject.other |
crystal structure |
en |
| dc.subject.other |
drug activity |
en |
| dc.subject.other |
drug design |
en |
| dc.subject.other |
model |
en |
| dc.subject.other |
mutant |
en |
| dc.subject.other |
myasthenia gravis |
en |
| dc.subject.other |
nonhuman |
en |
| dc.subject.other |
priority journal |
en |
| dc.subject.other |
rat |
en |
| dc.subject.other |
structure analysis |
en |
| dc.subject.other |
Amino Acid Sequence |
en |
| dc.subject.other |
Animals |
en |
| dc.subject.other |
Antibodies, Monoclonal |
en |
| dc.subject.other |
Autoantibodies |
en |
| dc.subject.other |
Binding Sites, Antibody |
en |
| dc.subject.other |
Computer Simulation |
en |
| dc.subject.other |
Crystallography, X-Ray |
en |
| dc.subject.other |
Humans |
en |
| dc.subject.other |
Immunoglobulin Fab Fragments |
en |
| dc.subject.other |
Mice |
en |
| dc.subject.other |
Models, Molecular |
en |
| dc.subject.other |
Molecular Sequence Data |
en |
| dc.subject.other |
Muramidase |
en |
| dc.subject.other |
Muscle, Skeletal |
en |
| dc.subject.other |
Myasthenia Gravis |
en |
| dc.subject.other |
Protein Conformation |
en |
| dc.subject.other |
Protein Folding |
en |
| dc.subject.other |
Protein Structure, Secondary |
en |
| dc.subject.other |
Rats |
en |
| dc.subject.other |
Receptors, Nicotinic |
en |
| dc.subject.other |
Software |
en |
| dc.title |
Crystal structure of Fab198, an efficient protector of the acetylcholine receptor against myasthenogenic antibodies |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1046/j.1432-1327.2001.02274.x |
en |
| heal.publicationDate |
2001 |
en |
| heal.abstract |
The crystal structure of the Fab fragment of the rat monoclonal antibody 198, with protective activity for the main immunogenic region of the human muscle acetylcholine receptor against the destructive action of myasthenic antibodies, has been determined and refined to 2.8 Å resolution by X-ray crystallographic methods. The mouse anti-lysozyme Fab D1.3 was used as a search model in molecular replacement with the AMORE software. The complementarity determining regions (CDR)-L2, CDR-H1 and CDR-H2 belong to canonical groups. Loops CDR-L3, CDR-H2 and CDR-H3, which seem to make a major contribution to binding, were analyzed and residues of potential importance for antigen-binding are examined. The antigen-binding site was found to be a long crescent-shaped crevice. The structure should serve as a model in the rational design of very high affinity humanized mutants of Fab198, appropriate for therapeutic approaches in the model autoimmune disease myasthenia gravis. |
en |
| heal.journalName |
European Journal of Biochemistry |
en |
| dc.identifier.issue |
13 |
en |
| dc.identifier.volume |
268 |
en |
| dc.identifier.doi |
10.1046/j.1432-1327.2001.02274.x |
en |
| dc.identifier.spage |
3685 |
en |
| dc.identifier.epage |
3693 |
en |